Videos

Both experts stress that the framework is not intended to overhaul physicians’ communication styles but rather to highlight overlooked areas.

Experts discuss the ways in which AI could transform patient care and improve physician workflows, particularly for benign prostatic hyperplasia.

Both urologists emphasized that Northwestern’s integrated structure and commitment to innovation allow any urologist within the network to contribute ideas and see them developed into practice.

Sandip M. Prasad, MD, MPhil, outlines 3 key takeaways from the ENVISION trial, which evaluated mitomycin for intravesical solution in patients with LG-IR-NMIBC.

Many clinicians do not explain how the consultation will unfold or clearly define the respective roles of physician and patient.

Rana R. McKay, MD, FASCO, details the key efficacy and safety findings from the phase 2 COMRADE trial.

Rian J. Dickstein, MD, provides an overview of detalimogene voraplasmid, currently being evaluated for the treatment of non–muscle invasive bladder cancer.

Panelists discuss how patients with early recurrent low-grade bladder cancer, especially those on an anticoagulant or with multiple risk factors, represent ideal candidates for ablative therapy with UGN-102 to break the cycle of repeated transurethral resection of bladder tumors and provide a paradigm shift from purely surgical management to shared decision-making between surgical and medical treatment options.

Timothy D. McClure, MD, offers his thoughts on how future advancements will inform the role for focal therapy in prostate cancer.

Jennifer A. Robles, MD, MPH, discusses the future for HoLEP in terms of innovation and wider integration into urologic practice.

Sandip M. Prasad, MD, MPhil, discusses the safety profile for mitomycin for intravesical solution based on data from the ENVISION trial.

Avani Desai emphasizes that inadequate or unclear parental leave policies carry significant consequences, particularly during residency.

Kevin Shee, MD, PhD, shares findings on factors associated with recurrence and treatment failure following HIFU for prostate cancer.

The tool is designed as a patient-facing application that can be used both during clinic visits and independently at home.

An expert summarizes that the evolving non–muscle-invasive bladder cancer treatment landscape emphasizes early therapy intensification and personalized management—leveraging advanced diagnostics and varied intravesical therapies—to better distinguish recurrence from progression, aiming to preserve bladder function and improve outcomes while minimizing overtreatment and radical surgery.

An expert summarizes that interpreting trial results requires understanding study design—such as reinduction strategies—and recognizing that regulatory, logistical, and practical factors will influence the adoption of new bladder cancer therapies, emphasizing the need for larger studies and thoughtful integration of efficacy with real-world considerations to guide personalized treatment decisions.

Daniel Canter, MD, shares his thoughts on the potential impact of 89Zr-girentuximab for kidney cancer management, if approved.

Kathryn H. Gessner, MD, PhD, outlines the clinical scenarios in which she finds genomic testing most useful.

Nicolette G. Payne, MD, pointed to the critical role of leadership and institutional culture in addressing burnout.

Panelists discuss how patients with recurrent low-grade bladder cancer, particularly women who may face additional anatomical challenges during transurethral resection of bladder tumor (TURBT) procedures, can benefit from UGN-102 as an alternative to repetitive surgical resections, addressing the TURBT treadmill phenomenon where patients undergo multiple procedures with diminishing returns.

Ultimately, Desai argues, increasing transparency in policies is not only about compliance but about fostering resident well-being and inclusivity.

Panelists discuss how patients currently on injectable androgen deprivation therapy can transition to oral options through an overlap period, and how stated drug interactions with androgen receptor pathway inhibitors have not been clinically significant in practice.

Joseph Song, MD, discusses his approach to patient selection for the SURE procedure, particularly in comparison to more invasive options such as PCNL.

Jennifer A. Robles, MD, MPH, highlights the impact of regional disparities in HoLEP access on patient care.

Timothy D. McClure, MD, outlines key findings from the PRESERVE trial, which evaluated IRE for prostate tissue ablation in patients with intermediate-risk prostate cancer.

Sandip M. Prasad, MD, MPhil, details key findings from the phase 3 ENVISION trial, which supported the approval of mitomycin intravesical solution in LG-IR-NMIBC.

An expert summarizes that although it is currently too early to determine optimal sequencing among bladder cancer therapies, emerging strategies involving combination treatments and immune system priming show promise for enhancing efficacy, particularly in high-risk patients, underscoring the need for further research to guide personalized treatment decisions.

An expert summarizes that Tara-002 offers a familiar, intravesical administration and manageable adverse effect profile similar to BCG, making it a safer and more easily adoptable option compared with systemic immunotherapies, especially important for preserving bladder function and quality of life in heavily treated BCG-unresponsive patients.

Suzanne B. Merrill, MD, FACS, unpacks key findings from the CREST trial and outlines data of interest from the POTOMAC and PATAPSCO trials, which are set to read out later this year.

Jack Andrews, MD; Alicia Morgans, MD, MPH; and Ashley Ross MD, PhD, discuss how trial design, inclusion criteria, and end points like radiographic progression-free survival vs overall survival impact clinical decision-making in prostate cancer treatment, emphasizing the importance of quality of life data and the shift from using ADT alone as standard care toward combination therapies in prostate cancer management.